Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups

Yabuuchi Hidetake; Kawanami Satoshi; Iwama Eiji; Okamoto Isamu; Kamitani Takeshi; Sagiyama Koji; Yamasaki Yuzo; Honda Hiroshi

首页> 外文期刊>Radiology >Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups

【24h】

Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups

机译：使用双输入灌注CT分析对NSCLC化疗治疗疗效的预测：Bevacizumab治疗中的比较，双剂铂类疗法，无贝伐单抗及其他非贝伐单抗治疗组

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose: To determine whether dual-input perfusion computed tomography (CT) can predict therapeutic response and prognosis in patients who underwent chemotherapy for non-small cell lung cancer (NSCLC).

机译：目的：确定双输入灌注计算机断层扫描（CT）可以预测接受非小细胞肺癌（NSCLC）化疗的患者的治疗响应和预后。

著录项

来源
《Radiology》 |2018年第2期|共11页
作者
Yabuuchi Hidetake; Kawanami Satoshi; Iwama Eiji; Okamoto Isamu; Kamitani Takeshi; Sagiyama Koji; Yamasaki Yuzo; Honda Hiroshi;
展开▼
作者单位

Kyushu Univ Grad Sch Med Sci Dept Hlth Sci Higashi Ku 3-1-1 Maidashi Fukuoka 8128582 Japan;

Kyushu Univ Grad Sch Med Sci Dept Clin Radiol Higashi Ku 3-1-1 Maidashi Fukuoka 8128582 Japan;

Kyushu Univ Grad Sch Med Sci Res Inst Dis Chest Higashi Ku 3-1-1 Maidashi Fukuoka 8128582;

Kyushu Univ Grad Sch Med Sci Res Inst Dis Chest Higashi Ku 3-1-1 Maidashi Fukuoka 8128582;

Kyushu Univ Grad Sch Med Sci Dept Clin Radiol Higashi Ku 3-1-1 Maidashi Fukuoka 8128582 Japan;

Kyushu Univ Grad Sch Med Sci Dept Clin Radiol Higashi Ku 3-1-1 Maidashi Fukuoka 8128582 Japan;

Kyushu Univ Grad Sch Med Sci Dept Clin Radiol Higashi Ku 3-1-1 Maidashi Fukuoka 8128582 Japan;

Kyushu Univ Grad Sch Med Sci Dept Clin Radiol Higashi Ku 3-1-1 Maidashi Fukuoka 8128582 Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词

相似文献

外文文献
中文文献
专利

1. Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups [J] . Yabuuchi Hidetake, Kawanami Satoshi, Iwama Eiji, Radiology . 2018,第2期

机译：使用双输入灌注CT分析对NSCLC化疗治疗疗效的预测：Bevacizumab治疗中的比较，双剂铂类疗法，无贝伐单抗及其他非贝伐单抗治疗组
2. AvaALL: Open-Label Randomized Phase 1Mb Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Continuous Bevacizumab (BV) Treatment Beyond Disease Progression in Patients (pts) With Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) After First-Line (1L) Treatment With BV Plus Platinum-Doublet Chemotherapy (CT) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla11期

机译：AvaALL：开放标签随机1Mb临床试验，评估在初次手术后晚期非鳞状非小细胞肺癌（NSCLC）患者病情进展之外，是否进行持续贝伐单抗（BV）治疗的标准治疗的有效性和安全性BV加上铂金双线化疗（CT）的线（1L）治疗
3. Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis [J] . Yi Liu, Hui-Min Li, Ran Wang Frontiers in Medicine . 2021,第a期

机译：将贝伐单抗加入铂基化学疗法的效力与安全作为先进非小细胞肺癌的一线治疗：META分析
4. Prediction of Glioblastoma Multiforme Response to Bevacizumab Treatment Using Diffusion and Perfusion Imaging [C] . Ehsan Abadi, Hamid Soltanian-Zadeh, Lisa Scarpace, Iranian Conference on Biomedical Engineering . 2015

机译：利用扩散和灌注成像预测胶质母细胞瘤对贝伐单抗治疗的响应
5. An economic analysis of the addition of bevacizumab to standard chemotherapy in patients with malignant pleural mesothelioma. [D] . Malacan, Jean. 2016

机译：恶性胸膜间皮瘤患者在标准化疗中加用贝伐单抗的经济分析。
6. Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L) [O] . Masayuki Takeda, Isamu Okamoto, Takeharu Yamanaka, 2012

机译：贝伐单抗治疗对疾病进展以外的影响：铂类化疗加贝伐单抗治疗晚期非鳞状非小细胞肺癌患者中多西他赛联合或不联合贝伐单抗的II期随机研究（WJOG 5910L）
7. Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups [O] . Hidetake Yabuuchi, Satoshi Kawanami, Eiji Iwama, 2018

机译：使用双输入灌注CT分析对NSCLC化疗治疗疗效的预测：Bevacizumab治疗中的比较，双剂铂类疗法，无贝伐单抗及其他非贝伐单抗治疗组

Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅